TikoMed AB, a Sweden-based biopharmaceutical company, and United States-based clinical research services company IQVIA announced on Thursday that they have entered into a strategic collaboration with the aim of expediting the development of TikoMed's lead drug platform candidate ILB, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation.
The partnership is intended to support TikoMed's clinical development, regulatory and commercial strategies. IQVIA said that it provides its therapeutic expertise, data and technology alongside flexible operating models to enable biopharma organisations such as TikoMed to expedite the clinical development and commercialisation of innovative products that improve patient lives.
The Connecting Architects advised TikoMed on this strategic collaboration.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007